In a welcome move, Jazz Pharmaceuticals saw its Relative Strength Rating improve from 64 to 71 on Friday.
IBD's unique RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves. See if Jazz Pharmaceuticals can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Jazz Pharmaceuticals is trying to complete a flat base with a 128.99 entry. See if the stock can break out in heavy volume.
Regarding fundamentals, Jazz Pharmaceuticals has posted two quarters of accelerating earnings growth. Sales gains have also increased during the same period.
The company earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
